

Beneficiary Information

| | | |
|---------------------------------|-------------------------------------|------------------------------|
| 1. Beneficiary Last Name: _____ | 2. First Name: _____ | |
| 3. Beneficiary ID #: _____ | 4. Beneficiary Date of Birth: _____ | 5. Beneficiary Gender: _____ |

Prescriber Information

| |
|--|
| 7. Prescribing Provider NPI#: _____ |
| 8. Prescriber DEA #: _____ |
| Requester Contact Information |
| Name: _____ Phone #: _____ Ext.: _____ |

Drug Information

| | | |
|--|---------------------|---------------------------------|
| 9. Drug Name: _____ | 10. Strength: _____ | 11. Quantity per 30 Days: _____ |
| 12. Length of Therapy (in days): <input type="checkbox"/> up to 30 <input type="checkbox"/> 60 <input type="checkbox"/> 90 <input type="checkbox"/> 120 <input type="checkbox"/> 180 | | |

Clinical Information**For initial therapy:****Asthma (answer questions 1-7)**

| |
|---|
| 1. Is the member age 12 or greater? <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 2. Does the member have a diagnosis of Asthma with eosinophilic phenotype with a pre-treatment serum eosinophil count of 150 cells/mcL or greater at screening (within the past six weeks prior to the request for Dupixent) or 300 cells/mcL or greater within 12 months prior to use, or sputum eosinophilic count greater than 3%? <input type="checkbox"/> Yes <input type="checkbox"/> No Please list eosinophilic count. _____ |
| 3. Does the member have Oral-corticosteroid-dependent asthma with at least 1 month of daily oral corticosteroid use within the last 3 months? <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 4. Is the member experiencing inadequate control of asthma symptoms after a minimum of 3 months of compliant use of one of the following: a. Inhaled corticosteroids and long acting beta2 agonist <input type="checkbox"/> Yes <input type="checkbox"/> No b. Inhaled corticosteroids and long acting muscarinic antagonist <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 5. Is Dupixent being used for the relief of acute bronchospasm or status asthmaticus? <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 6. Is Dupixent being used as dual therapy with another monoclonal antibody for the treatment of Asthma? <input type="checkbox"/> Yes <input type="checkbox"/> No |

For continuation of therapy:**Asthma (answer questions 1-7 above and answer questions 7 & 8)**

| |
|--|
| 7. Has the member experienced clinical benefit as evidenced by a documented response of decreased asthma exacerbations from baseline? <input type="checkbox"/> Yes <input type="checkbox"/> No |
| 8. Are medical records attached to this request that document the member's current asthma status and response to Dupixent treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No |

Signature of Prescriber: _____ Date: _____

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.